Literature DB >> 20160743

Biosimilars: evidential standards for health technology assessment.

D A Hughes1.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20160743     DOI： 10.1038/clpt.2009.112

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  5 in total

Review 1.  Biosimilars and market access: a question of comparability and costs?

Authors:  Steven Simoens; Gilbert Verbeken; Isabelle Huys
Journal:  Target Oncol       Date:  2012-01-17       Impact factor: 4.493

2.  Generic and therapeutic substitutions in the UK: are they a good thing?

Authors:  Martin G Duerden; Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

3.  Biosimilar medicines and cost-effectiveness.

Authors:  Steven Simoens
Journal:  Clinicoecon Outcomes Res       Date:  2011-02-10

Review 4.  Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

Authors:  María-Isabel Farfan-Portet; Sophie Gerkens; Isabelle Lepage-Nefkens; Irmgard Vinck; Frank Hulstaert
Journal:  Eur J Health Econ       Date:  2013-11-23

5.  Economic evaluation of biosimilars for reimbursement purposes - what, when, how?

Authors:  Evelien Moorkens; Hannah Broux; Isabelle Huys; Arnold G Vulto; Steven Simoens
Journal:  J Mark Access Health Policy       Date:  2020-03-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.